NanoBUP

**NanoBUP** is Nanopharmaceutics' proprietary nanoparticle-enabled, orally swallowed capsule formulation of **buprenorphine** for opioid use disorder and pain management. The current sponsor description identifies buprenorphine as the active ingredient and positions NanoBUP as an alternative to sublingual buprenorphine; it is intended to provide oral absorption with a lower peak plasma concentration than sublingual administration. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor, supporting opioid-withdrawal suppression, maintenance treatment, and analgesic activity. The sponsor reports completed Phase 1 and Phase 2 studies and describes NanoBUP as in Phase 2 clinical development. ([nanopharmaceutics.com](https://www.nanopharmaceutics.com/nanobup))

Brand names

NanoBUP

Other names

NanoBUP Oral Swallowed Capsule